Tuesday, July 9, 2024

CATEGORY

Sanofi

Sanofi’s Frexalimab Shows Promise in Reducing MS Nerve Cell Damage

Frexalimab, a CD40L monoclonal antibody developed by Sanofi, has shown significant potential in treating relapsing multiple sclerosis (MS) by reducing a key biomarker of...

Riliprubart Shows Promising Results in Treating Chronic Inflammatory Demyelinating Polyneuropathy

Sanofi’s complement C1s inhibitor, riliprubart, has shown encouraging efficacy and safety for participants with chronic inflammatory demyelinating polyneuropathy (CIDP) in an ongoing phase 2...

Cost Concerns: NICE Would Reject Sarclisa Even at Zero Cost, Says Sanofi

Cost concerns have driven Sanofi to strongly criticize National Institute for Health and Care Excellence's (NICE) decision not to recommend the use of Sarclisa...

Inactivated Polio Vaccines Production in Africa: Sanofi and Biovac Announce Strategic Partnership

Sanofi and Biovac have announced a partnership to produce inactivated polio vaccines in Africa. This agreement aims to support regional manufacturing capabilities and meet...

Therapy Setbacks and Advances: AstraZeneca’s Truqap, Sanofi’s New Partnership, and More

AstraZeneca faced a setback with its new breast cancer therapy, Truqap. The Capitello-290 trial, which evaluated Truqap in combination with chemotherapy for treating “triple-negative”...

Polyarticular Juvenile Idiopathic Arthritis: FDA Approves Regeneron and Sanofi’s Kevzara for Treatment

Polyarticular juvenile idiopathic arthritis (pJIA) treatment has advanced with the Food and Drug Administration's (FDA) approval of Kevzara (sarilumab), developed by Regeneron and Sanofi,...

Heartburn Medication Zantac: Sanofi Settles 4,000 U.S. Lawsuits, Continues Delaware Defense

Sanofi has finalized a settlement to resolve approximately 4,000 personal injury lawsuits across the United States, excluding Delaware, concerning its heartburn medication, Zantac. These...

FDA Review Extended for Dupixent in COPD Treatment

The FDA has extended the priority review for Dupixent as an add-on maintenance treatment for adults with uncontrolled COPD with type 2 inflammation. The...

Sanofi Expands Rare Disease Pipeline with Inhibrx Acquisition

Sanofi has completed its acquisition of Inhibrx, Inc., marking a significant expansion of its rare disease pipeline. This acquisition, finalized on May 30, 2024,...

FDA Priority Review for Sarclisa in Multiple Myeloma Treatment

The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for the investigational use of Sarclisa...

Latest news